A phase II non-randomized open labeled trial for preoperative circadian chronomodulated hepatic arterial infusion (HAI) chemotherapy combined with panitumumab for liver metastases from colorectal cancer.

A phase II non-randomized open labeled trial for preoperative circadian chronomodulated hepatic arterial infusion (HAI) chemotherapy combined with panitumumab for liver metastases from colorectal cancer. - A trial for preoperative circadian chronomodulated HAI chemotherapy combined with panitumumab for liver metastases from colorectal cancer.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009091

Enrollment

Registered

2012-10-15

Start date

2012-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver metastases from colorectal cancer

Interventions

Chronomodulated HAI chemotherapy group The patients of this group will receive 6 cycles of chronomodulated HAI chemotherapy with 5-FU/LV/L-OHP before hepatectomy for liver metastases from colorectal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who will undergo hepatectomy for liver metastases from colorectal cancer. The operation is not emergency.

Exclusion criteria

Exclusion criteria: The patient with double cancer or multiple colorectal cancer

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
The incident rate of adverse events for preoperative chemotherapy and the morbidity rate after hepatectomy	—

Countries

Japan

Contacts

Public ContactKuniya Tanaka

Yokohama city university graduate school of medicine Department of gastroenterological surgery

ktrj112@urahp.yokohama-cu.ac.jp045-787-2650

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026